press release | iECURE - Part 2

Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle Disorder to be Presented in Presidential Symposium at ASGCT 2022

May 18, 2022/in news, press release/by David Anderson

May 18, 2022

iECURE Announces Presentation of Data on its Gene Editing Approach at the American Society of Cell and Gene Therapy Annual Meeting

May 2, 2022/in news, press release/by David Anderson

May 3, 2022

iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders

April 25, 2022/in news, press release/by David Anderson

April 25, 2022

iECURE Expands Leadership Team with the Appointment of Mark Semanick as VP and Head of Technical Operations and Brad Dickerson as VP of Project Management & Patient Advocacy

February 1, 2022/in news, press release/by David Anderson

February 1, 2022

iECURE Partners to Develop Next-Generation Liver-Targeted Lipid Nanoparticles with University of Pennsylvania

December 16, 2021/in news, press release/by eallison

December 16, 2021

iECURE Bolsters Senior Management Team with Appointment of David Garrett as Chief Financial Officer

December 7, 2021/in news, press release/by eallison

December 06, 2021

iECURE Appoints Brian Di Donato to Board of Directors

September 15, 2021/in news, press release/by eallison

September 15, 2021

iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

September 15, 2021/in news, press release/by eallison

September 9, 2021

Copyright 2024 – iECURE | Privacy Notice | Terms of Service | Cookie Notice | Expanded Access Policy